WO2000018430A3 - Live virus vaccines to protect primates from hiv-1 infection and disease - Google Patents
Live virus vaccines to protect primates from hiv-1 infection and disease Download PDFInfo
- Publication number
- WO2000018430A3 WO2000018430A3 PCT/US1999/022349 US9922349W WO0018430A3 WO 2000018430 A3 WO2000018430 A3 WO 2000018430A3 US 9922349 W US9922349 W US 9922349W WO 0018430 A3 WO0018430 A3 WO 0018430A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- disease
- infection
- live virus
- virus vaccines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62681/99A AU6268199A (en) | 1998-09-29 | 1999-09-28 | Live virus vaccines to protect primates from hiv-1 infection and disease |
EP99949907A EP1109575A2 (en) | 1998-09-29 | 1999-09-28 | Live virus vaccines to protect primates from hiv-1 infection and disease |
CA002345959A CA2345959A1 (en) | 1998-09-29 | 1999-09-28 | Live virus vaccines to protect primates from hiv-1 infection and disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10214398P | 1998-09-29 | 1998-09-29 | |
US60/102,143 | 1998-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000018430A2 WO2000018430A2 (en) | 2000-04-06 |
WO2000018430A3 true WO2000018430A3 (en) | 2000-07-06 |
Family
ID=22288338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/022349 WO2000018430A2 (en) | 1998-09-29 | 1999-09-28 | Live virus vaccines to protect primates from hiv-1 infection and disease |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1109575A2 (en) |
AU (1) | AU6268199A (en) |
CA (1) | CA2345959A1 (en) |
WO (1) | WO2000018430A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2929937C (en) * | 2012-09-11 | 2020-01-07 | The Regents Of The University Of California | Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050070A1 (en) * | 1997-05-02 | 1998-11-12 | University Of Kansas Medical Center | Live virus vaccines to protect primates from hiv-1 infection and disease |
-
1999
- 1999-09-28 CA CA002345959A patent/CA2345959A1/en not_active Abandoned
- 1999-09-28 WO PCT/US1999/022349 patent/WO2000018430A2/en not_active Application Discontinuation
- 1999-09-28 EP EP99949907A patent/EP1109575A2/en not_active Withdrawn
- 1999-09-28 AU AU62681/99A patent/AU6268199A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050070A1 (en) * | 1997-05-02 | 1998-11-12 | University Of Kansas Medical Center | Live virus vaccines to protect primates from hiv-1 infection and disease |
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
CA2345959A1 (en) | 2000-04-06 |
WO2000018430A2 (en) | 2000-04-06 |
EP1109575A2 (en) | 2001-06-27 |
AU6268199A (en) | 2000-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001010456A3 (en) | Peptides that block viral infectivity and methods of use thereof | |
CA2243570A1 (en) | Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv | |
EP1820853A3 (en) | Recombinant influenza viruses for vaccines and gene therapy | |
WO1995000638A3 (en) | Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection | |
ZA964694B (en) | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection. | |
DE60110822D1 (en) | PREPARING FOR IMMUNIZING AGAINST THE AIDS VIRUS | |
AUPO784197A0 (en) | Treatment of nasopharyngeal carcinoma | |
HK1044799A1 (en) | Immunoligically significant herpes simplex virus antigens | |
WO2001000232A3 (en) | Use of cpg as an adjuvant for hiv vaccine | |
AU8499901A (en) | Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization | |
WO2004045529A3 (en) | West nile virus vaccine | |
WO2003011893A3 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
WO2005028496A3 (en) | Vaccine for treatment and prevention of herpes simplex virus infection | |
MY144492A (en) | Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types | |
KR100725637B1 (en) | Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein | |
AU2002219881A1 (en) | Methods and compositions for the treatment of human immunodeficiency virus infection | |
WO2005097179A3 (en) | Stabilised tat antigen and the use thereof for anti-hiv vaccination | |
WO2000018430A3 (en) | Live virus vaccines to protect primates from hiv-1 infection and disease | |
WO2004029201A3 (en) | Peptide derivative fusion inhibitors of hiv infection | |
AU4111600A (en) | The use of gssg reductase for the therapy and prophylaxis of hiv infected patients | |
WO2002047720A3 (en) | Treatment and prevention of ebv infection and ebv-associated disorders | |
WO2003045428A3 (en) | Use of a technically modified cell as a vaccine for treating tumoral disease | |
NO20013101L (en) | Outer surface proteins, their genes and their use | |
WO2002046214A3 (en) | Immunomodulatory protein derived from the yaba monkey tumor virus | |
WO2003017943A3 (en) | Therapeutic compositions and methods for treating viral infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2345959 Country of ref document: CA Ref document number: 2345959 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999949907 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00263/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09806162 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999949907 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999949907 Country of ref document: EP |